The FDA has approved nerve stimulation for treatment of episodic and chronic cluster headaches and acute migraines. The findings, detailed in a study published online Feb. 13 in PLOS ONE, could help personalize treatment for PTSD, which according to the National Institute of Mental Health impacts roughly 3.6 percent of U.S. adults per year.